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Introduction
Acute coronary syndromes, namely, unstable angina
and myocardial infarction, remain a major cause of
morbidity and mortality (1). The light has been shed
on the pathogenesis of these syndromes by recent developments, such as the increased use of coronary
angiography in patients with acute coronary syndromes
over the last two decades, a better understanding of
platelet function and the coagulation pathways, and
the development of advanced percutaneous techniques,
percutaneous transluminal coronary angioplasty (PTCA)
and coronary angioscopy.
The development and availability of the GPIIb/IIIa
inhibitors has initiated a new era in our approach to
these patients. Several studies are currently under way
assessing the safety and usefulness of these compounds in the setting of percutaneous coronary interventions, acute coronary syndromes and in the secondary prevention of coronary artery disease. This
review summarizes the current state of knowledge of
the use of these inhibitors in the practice of cardiology.
Pathophysiology of Acute Coronary Syndromes
Unstable angina is defined as the evolving pattern
of chest pain with multiple manifestations that are distinct from those of stable angina (2). Clinical and laboratory investigations have made it clear that the pathophysiology of unstable angina differs from that of
stable angina. There is a loss of endothelial integrity,

exposure of the subendothelial matrix and activation of
the cellular components of the atherosclerotic plaque
which eventually results in platelet activation and
thrombus formation (2-5). Fitzgerald et al. assessed
the indices of platelet activation in patients with stable
and unstable coronary artery disease. To avoid the artifactual stimulation of platelets during venosection,
they determined the urinary excretion of metabolites
of thromboxane and prostacyclin (6). Significant platelet activation was demonstrated in patients with unstable angina and acute myocardial infarction, whereas
no such activation was evident in patients with stable
coronary artery disease. Furthermore, detailed histologic studies have demonstrated layers of platelet
thrombi in different stages of organization at sites of
coronary occlusion (4, 7). Platelet activation then leads
to coronary occlusion either by obliterating the artery
by thrombus or by causing coronary artery spasm by
platelet derived vasoactive compounds (8). The same
sequence of events could be responsible for complications of such as abrupt closure. Balloon angioplasty
disrupts the continuity of the endothelium and exposes
subendothelial substrates such as collagen, vWF, fibronectin, vitronectin and laminin. As in the acute coronary syndromes, this injury triggers platelet activation
and thrombus formation.
As early as 1912, Herrick postulated that the triggering event of myocardial infarction was coronary
thrombosis (9). DeWood proved Herrick’s hypothesis
by demonstrating angiographically that total occlusion
of the coronary artery by a thrombus was present in
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87% of patients evaluated within 4 hours of symptom
onset (10). Plasminogen activation by thrombolytic
treatment in these patients dissolves the fibrin elements of the thrombus and reestablishes the coronary
patency (11).
Role of Platelets in Acute Coronary Syndromes
The therapeutic benefits of aspirin and/or thrombolytic agents after myocardial infarction lend support
to the critical role of platelets and thrombus formation
in the pathogenesis of acute coronary syndromes.
Large scale clinical studies revealed that the early administration of thrombolytic agents was associated
with significant reduction in mortality (12). Another
intervention that conclusively demonstrated mortality
benefit in patients with acute myocardial infarction
was the administration of aspirin. A multicenter, multinational study, the Second International Study of Infarct Survival (ISIS-2) randomized 17.187 patients
with acute myocardial infarction to receive 162.5 mg
of oral aspirin daily for one month, or placebo (12).
At 35 days, there were statistically significant, reductions in vascular mortality (23%) and reinfarction
(55%) in the group receiving aspirin. Hence, drugs
that dissolve thrombi, such as thrombolytic agents
and/or drugs that prevent clot propagation, such as
antiplatelet agents and/or anticoagulant agents, are
widely used in acute coronary syndromes.
Currently, the proven benefit observed with aspirin
administration in the setting of acute myocardial infarction would make it unethical to design placebocontrolled studies to investigate antiplatelet therapy.
However, many patients have recurrent ischemic
events despite being on aspirin therapy (13). Thus, an
initially successful response to thrombolytic therapy
may be countered by subsequent reocclusion (14).
This has stimulated the search for the ideal adjunctive
agent in attempts to inhibit coronary thrombus formation.
Platelet Adhesion and Aggregation
The processes of thrombosis and hemostasis are
mediated via two distinct but complementary functions
of platelets, namely adhesion and aggregation. Any discontinuity in endothelial cell coverage or exposure of
the sub-endothelial matrix is met with rapid platelet
adhesion to the vessel wall. Exposure the subendothelial substrates such as collagen, vWF, fibronectin, vitronectin and laminin is crucial in platelet adhesion. Adhesion causes platelet activation, which
stimulates several intracellular pathways (15). Throm-
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boxane A2, thrombin, norepinephrine, collagen, and
adenosine diphosphate are some of the key players of
these intracellular pathways (15,16). They act through
different receptors to mobilize intracellular calcium
mobilization and platelet degranulation (16,17). Platelets then release agonists of aggregation such as adenosine diphosphate, serotonin, and thromboxane A2; all
of which activate surrounding platelets to form the
platelet plug (15,16,17). Aspirin prevents platelet aggregation by reducing the synthesis of thromboxane
A2, however platelet aggregation can still be initiated
by other agonists, such as thrombin, subendothelial
collagen, or, in the setting of PTCA, by stainless steel.
In addition, aspirin inhibits the endothelial cell production of prostacyclin, a potent platelet inhibitor and
vasodilator. Therefore, aspirin may not be the ideal
antiplatelet agent in acute coronary syndromes.
Glycoprotein IIb/IIIa Receptor
Platelet functions such as adhesion or aggregation
require recognition of a diverse number of proteins,
including extracellular matrix proteins such as vWF,
collagen, fibronectin, vitronectin and laminin. Thus,
glycoprotein receptors on the platelet membrane are
essential for normal platelet function.
Glycoprotein IIb/IIIa is the most prevalent protein
on the platelet surface (18). There are approximately
50,000 molecules on the surface of unactivated platelets. It is a member of the integrin family of the adhesion receptors (19). The integrins are a family of
receptors that mediate many cell-to-cell and cell-tomatrix interactions. All integrins are heterodimers of α
and β subunits. GPIIb/IIIa is present only on the surface of platelets and cells of megakaryocyte lineage
(18). It is a heterodimer subunit composed of αIIb and
β3 subunits (Figure 1) (19).
If the extracellular matrix becomes exposed by disruption of the overlying endothelial cells, platelets may
attach to the exposed areas. This attachment makes
the platelets more adhesive by inside-out activation of
the GPIIb/IIIa receptor on the platelet surface (19).
The integrin then captures circulating molecules like fibrinogen or von Willebrand Factor that subsequently
form bridges linking the platelets and the matrix (Figure 2). Interestingly, several studies revealed that the
concentration of circulating fibrinogen is a potent risk
factor for acute coronary syndrome, suggesting a critical role for fibrinogen in the pathogenesis of acute
coronary syndromes (20). Additional studies have
linked ex vivo platelet reactivity to outcome in patients
who have suffered a myocardial infarction (21).
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platelet GP IIb/IIIa abnormality. The measurements of
GP IIb/IIIa in thrombasthenic patients have revealed
that some patients with nearly absent GP IIb/IIIa have
minimal bleeding complications, and some patients
with substantial amounts of GP IIb/IIIa can present
with recurrent and severe bleeding (23). It has been
suggested that cells other than megakaryocytes and
platelets may be abnormal in Glanzman’s thrombasthenia, as the GP IIIa component of the integrin
receptor is present in many tissues as the β subunit
of the vitronectin receptor. This could be the basis for
variability in bleeding symptoms among
thrombasthenic patients. These clinical observations provided
insight stimulating the development of GP IIb/IIIa receptor as a therapeutic target in patients with coronary artery disease.

Glanzman’s thrombasthenia is an inherited abnormality in GPIIb/IIIa expression or function that impairs platelet aggregation and results in a bleeding disorder. This disorder formed the “knock-out” model
for the early research with this receptor. Marjorie
Zucker studied the platelets of a young male patient
with Glanzman thrombasthenia almost three decades
ago (22). Tests of coagulation were normal, the bleeding time was > 15 minutes, and there was no clot retraction in whole blood at 1 hour. She also observed
that the patient’s platelets were severely deficient in fibrinogen. This led to the conclusion that fibrinogen
binding is critical for platelet aggregation. Recent studies demonstrated that platelet aggregation requires the
binding of fibrinogen and von Willebrand factor to the
receptor, GP IIb/IIIa, on the platelet surface (Figure
2) (18).

Early onset coronary artery disease is a polygenic
disease, which progresses through the interaction between the effects of multiple genes and several environmental factors. Recently, Weiss et al reported a
high frequency of a particular polymorphism, PlA2, of
the gene encoding glycoprotein IIIa in kindreds with a
high prevalence of premature myocardial infarction
(24). Furthermore, the same researchers observed a
strong association between the PlA2 polymorphism of

Clinical observations have demonstrated that spontaneous, severe bleeding is uncommon among patients
with thrombasthenia (23). Minor bleeding events such
as purpura, epistaxis and gingival hemorrhage are almost constant features of this disease; however, with
supportive care the prognosis is usually excellent (23).
Unlike hemophilia, the severity of bleeding in thrombasthenia does not correlate with the severity of the
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the GP IIIa gene and coronary thrombosis. This association was strongest in people who had suffered
coronary events before the age of 60. A report published in The Lancet entitled “Clues to the death of an
Olympic champion” linked this polymorphism to the
death of Sergei Grinkov, aged 28, two-time Olympic
skating gold medalist who collapsed suddenly while
training on the ice-rink (25).
Glycoprotein IIb/IIIa Antagonists
Agonists of platelet aggregation, such as adenosine
diphosphate, serotonin, and thromboxane A2, activate
adjacent platelets to form the platelet plug(15,16,
17). Irrespective of the agonist, the final common
pathway leading to the platelet activation is mediated
by the binding of fibrinogen to the GP IIb/IIIa receptor (26,27). Platelet activation from any mechanism results in a conformational change in the GPIIb/
IIIa receptor that enables binding of the cognate ligand, fibrinogen. This universal role of the GPIIb/IIIa
receptor has made it a potential therapeutic target in
acute coronary syndromes. In particular, it raises the
possibility that the blocking of this receptor by an antibody could completely prevent the final common
pathway of platelet aggregation.
Using fibrinogen-coated beads as a screening assay,
Coller et al. were able to develop monoclonal antibodies that blocked the interaction of platelets with fibrinogen (28). This seminal finding led to the development of several inhibitors of this receptor. These
agents can be classified as competitive and noncompetitive inhibitors of fibringen binding, depending
on their pharmacokinetics and pharmacodynamics.
The F(ab) fragment of the human-murine chimeric antibody (c7E3) is the only non-competitive inhibitor of
fibrinogen binding currently available. As originally developed, the monoclonal antibody 7E3 was entirely
murine in composition. However, strong immunogenecity with the murine antibody and severe thrombocytopenia with the human antibody lead to the de-
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velopment of genetically engineered chimeric monoclonal c7E3 Fab, which has 75% human and 25%
murine composition. It occupies the GPIIb/IIIa receptor
permanently. It has an extended half-life, which may
be advantageous in the long-term. In addition to the
affinity on αIIb β3 (GP IIb/IIIa), c7E3 also block vitronectin receptors, which are known to stimulate
smooth muscle cell proliferation and migration (29).
These properties make this agent more appealing to
the interventional cardiologist, as smooth muscle cells
are vital in the processes of restenosis after a percutaneous coronary intervention. The reversal of the
effects of cE73 in cases of an adverse effect such as
bleeding can occur only by externalization of new receptors on the platelet surface or by supplying new
platelets either from the bone marrow or externally
by platelet transfusion.
There are several competitive inhibitors of GPIIb/
IIIa receptor being developed, including a cyclic peptide
agent (Integrelin), the non-peptide mimetic (tirofiban),
and orally active agents such as (xemilofiban) (Figure
3). The binding of the competitive inhibitors to the integrin receptor is concentration-dependent and reversible (30). Thus, anti-platelet effects are directly related to the duration of the infusion and can be
readily reversed by stopping the infusion. Shortened
biological half-life of competitive inhibitors may prevent severe bleeding complications and improve the
safety profile.
Use of GPIIb/IIIa in the Setting of Percutaneous
Coronary İntervention
Acute or abrupt closure of dilated vessel after percutaneous transluminal coronary angioplasty (PTCA)
occurs in 2-8% of patients (31,32), and is responsible
for virtually all serious in-hospital morbidity and mortality after PTCA. The pathophysiologic mechanisms of
acute coronary artery occlusion after successful PTCA
are probably multifactorial and involve platelet activation and thrombus formation following disruption of
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the endothelial layer by balloon and exposure of the
extracellular matrix to the platelets. The same sequence of events occurs in acute coronary syndromes
following natural rupture of the unstable lipid-rich
plaque. Starting from this paradigm, several large
trials were conducted that assessed the utility of
GPIIb/IIIa inhibitors after coronary intervention.
Four large trials, using three different agents, have
been published within the past two years: ; the Evaluation of c7E3 In Preventing Ischemic Complications
(EPIC) (33) and the Evaluation of PTCA to Improve
Long-term Outcome by c7E3 (EPILOG) both using the
antibody fragment abciximab (ReoPro) (34); the Integrilin to Minimize Platelet Aggregation and Prevent
Coronary Thrombosis II (IMPACT II) trial evaluating
the peptide Integrilin (35); and the Randomized Efficacy Study of Trofiban for Outcomes and Restenosis
(RESTORE) using the non-peptide mimetic trofiban
(Aggrastat) (36) (Table 1).
Table 1.
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Phase III Clinical Trials Evaluating Glycoprotein IIb/IIIa
Inhibitors after Coronary Intervention

Trial

Agent

Sample Size

Epic

c7E3 Fab

2099

Epilog

c7E3 Fab

2792

Impact II

Integrelin

4010

Restore

Tirofiban

2500

The first GPIIb/IIIa antagonist tested in the setting
of percutaneous coronary intervention was abciximab
in the EPIC study. Nearly 2100 patients were randomized after percutaneous transluminal coronary angioplasty to receive placebo, a bolus of abciximab, or
an identical bolus of abciximab followed by a 12 hour
infusion. The bolus dose of abciximab was started at
least 10 minutes before the procedure and given over
a 5 minute period. All patients were also treated with
aspirin and heparin. Heparin was given intravenously
in an initial bolus dose of 10.000 to 12.000 units.
Activated clotting time was maintained at 300 to 350
seconds during the procedure. A 35% reduction in the
ischemic endpoints (which included a composite of
death, nonfatal myocardial infarction, and repeat revascularization) at 30 days was noted after the use of
abciximab bolus and infusion. The benefit largely persisted at 6 months with a 23% reduction in the same
endpoints (33). However, this benefit was at the expense of a doubling of bleeding rates.
To further explore the optimal dosing strategy of
heparin in the setting of c7E3 administration, another
prospective, double-blind trial, EPILOG, randomly assigned patients undergoing percutaneous coronary revascularization at 69 centers to receive abciximab with
standard-dose heparin (initial dose of 100 U per kilogram of body weight), abciximab with low dose heparin (initial dose of 70 U per kilogram of body weight),
or placebo with standard-dose heparin. The end points
were death from any cause, myocardial infarction, or
urgent revascularization. The Safety and Efficacy Monitoring Committee recommended stopping the study
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after the enrollment of only 2792 of the planned
4800 subjects in view of the finding at interim analysis of a significant reduction in primary-outcome combined endpoints of death and myocardial infarction in
the treatment arms (5.2% versus 11.7% in the placebo group) (34). There were no significant differences among the groups in the risk of major bleeding,
although minor bleeding was more common among
groups receiving abciximab with standard dose heparin. This benefit persisted at the 6th month of followup. Similar benefit and safety profiles were observed
at 2 days with competitive inhibitors in IMPACT II (Integrelin) and RESTORE (Tirofiban) trials; however, by
the 30th day there was a significant loss in the reduction of ischemic endpoints (35, 36). The loss of
long-term benefit may be related to the short biological half-lives of these agents, or to their more specific effects on the GP IIb/IIIa receptor rather than on
the vitronectin receptor.
These results suggest that each GPIIb/IIIa inhibitor
possesses specific advantages and disadvantages. Abciximab has, in addition to a long biological half-life,
a crossreactivity with other receptors, including vitronectin and MAC-1. These receptors may play a key
role in the processes of restenosis after coronary intervention (29). On the other hand, the short elimination half-life of competitive inhibitors may improve
their safety profile and decrease the incidence of severe bleeding complications after the use of these
agents.
In summary, these trials have shown that the
blockade of platelet glycoprotein IIb/IIIa receptor can
reduce ischemic complications after percutaneous coronary intervention.
Use of GPIIb/IIIa in The Setting of Unstable
Angına
As with abrupt closure after coronary intervention,
platelet aggregation is the key event in acute coronary
syndromes. Therefore, one might expect a similar improvement in outcome with GP IIb/IIIa blockade in the
setting of acute coronary syndromes. However, less is
known about the role of these agents in unstable angina and/or acute myocardial infarction.
Several large-scale trials have evaluated this new
therapy in patients with unstable angina. The results
of the CAPTURE study (Chimeric 7E3 Antiplatelet
Therapy in Unstable Angina Refractory to Standard
Treatment) were announced in 1995. The study was
designed as a placebo controlled study of c7E3 Fab in
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1400 patients with refractory unstable angina scheduled for percutaneous coronary intervention in 75 clinical centers in Europe, Israel, and Canada (37). In this
large trial, patients were treated with a bolus
(0.25mg/kg) plus an infusion (10µg/min) of c7E3 Fab,
beginning 18 to 24 hours before the PTCA, and continuing through 1 hour following PTCA. The Safety
and Efficacy Monitoring Committee recommended
stopping the study after enrollment of 1050 subjects
in view of a significant reduction in the primary clinical composite endpoints of the trial: death, myocardial
infarction or need for urgent intervention (11.3% versus 15.9% in the placebo group). Major bleeding was
uncommon, but occurred more often with abciximab
than with placebo (3.8% versus 1.9%). Using the
same agent, van den Brand et al. reported an improved clinical course in the coronary lesion morphology in patients with unstable angina who were refractory to medical treatment (38). Sixty patients
were randomized to c7E3 or placebo after initial angiography had demonstrated a culprit lesion amenable
to angioplasty. After administration by bolus and infusion of c7E3, angiography was repeated and angioplasty was performed. Major events, defined as
death, MI and urgent intervention, were reduced in
the c7E3 group (P=0.03). Quantitative angiography
showed an improvement in the percentage luminal diameter and the resolution of intracoronary thrombi as
well as an improvement in TIMI flow grade in the
c7E3 group.
Theroux et al. published their observations with lamifiban, a nonpeptide, competitive GP IIb/IIIa inhibitor
(39). In this prospective, dose-ranging, double-blind
study, 365 patients with unstable angina were randomized to an infusion of 1, 2, 4, or 5 mg/minute of
lamifiban for 72 to 120 hours, or to placebo. All doses of lamifiban-protected patients with unstable angina
from severe ischemic events during a 3-to 5-day infusion, and reduced the incidence of death and infarction at 1 month (2.5% versus 8.1% in the placebo group). Schulman et al. reported that integrelin,
another competitive inhibitor of GPIIb/IIIa, reduced the
number and duration of ischemic events detected during Holter monitoring (8.41 + 5.29 minutes versus
26.2 + 9.8 minutes over 24 hours) in patients with
unstable angina pectoris when compared with aspirin
and standard anti-ischemic treatment (40).
Future trials will hopefully shed more light on the
potential role of glycoprotein IIb/IIIa blockade in the
setting of unstable angina.
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Use of GPIIb/IIIa in the Setting of Acute Myocardial Infarction
The usual cause of myocardial infarction in humans
is an occlusive thrombus in the coronary artery (9).
Over the last decade, the effective use of thrombolytic
therapy has started a new era in the treatment of this
major cause of morbidity and mortality. Appropriate
administration of thrombolytic therapy to patients with
acute myocardial infarction is associated with a reduction in mortality (12). The success of thrombolytic
therapy stems from its ability to activate plasminogen,
lyse the occlusive thrombus, and restore the blood
flow in 70% of the infarct-related arteries (41). However, about 30% of occluded infarct related arteries
still cannot be reperfused even with the best available
regimen of thrombolytic therapy. Additionally, in the
initial trials assessing thrombolytic therapy, the incidence of coronary occlusion from rethrombosis was
approximately 20%, and the incidence of reinfarction
was 10% (42). Most of these occlusions occurred in
the first 24 hours. One plausible cause of resistance
to thrombolytic therapy is the presence of platelet-rich
thrombus. Platelets are the richest source of circulating plasminogen activator inhibitor (PAI-1), diminishing the effectiveness of exogenously administered
plasminogen activators (streptokinase or t-PA). Patients who undergo coronary thrombolysis with either
streptokinase (43) or t-PA (44) exhibit an increase in
their urinary excretion of metabolites of thromboxane,
consistent with the activation of platelets by these
thrombolytic agents. The therapeutic benefit of combined antiplatelet therapy with thrombolytic therapy
was strongly demonstrated in the ISIS-2 study, where
the combination resulted in a doubling in the reduction
of mortality that was observed in patients treated
with either aspirin or streptokinase alone (12). In a
chronic, canine model of coronary thrombosis, Fitzgerald et al. demonstrated that tPA 10 mg/kg/min induced reperfusion in 55 ± 7 minutes, but was associated with complete reocclusion in 9/10 animals.
Reocclusion was prevented by the combination of t-PA
and c7E3 (45). Therefore, the use of GP IIb/IIIa inhibitors along with thrombolytic therapy may potentially improve patency of infarct vessels, reduce vessel
closure, and the incidence of reinfarction. Gold et al.
administered c7E3 Fab to patients who had angiographic occlusion of infarct-related artery in the
setting of acute anterior myocardial infarction (46).
GP IIb/IIIa blockade resulted in normal blood flow at
the infarct-related artery without any further inter-

vention in 7 out of 13 patients. c7E3 Fab antibody
also suppressed the expression of PAI-1 by cultured
microvascular cells (47); therefore, this antibody may
have a beneficial effect on the fibrinolytic balance of tPA:PAI-1 along with the well known anti-platelet effects.
The first large-scale phase III trial of these agents
after myocardial infarction is the PARADIGM study.
This study will evaluate the use of competitive, nonpeptide inhibitor lamifiban in combination with front-loaded
t-PA after myocardial infarction. ASSENT-II, HERO-II,
SPEED, GUSTO 4, APPLAUD and SYMPHONY are
some of the other acronyms for other large-scale
studies that will prospectively assess these novel
agents in the setting of acute myocardial infarction
(30).
Conclusions
GP IIb/IIIa receptor-based therapy has the potential
for a broad application in acute coronary syndromes
and percutaneous coronary interventions. The risk of
bleeding can be minimized by adjusting the adjunctive
treatments, as shown in the EPILOG trial (34). However, there are still unresolved issues related to the
use of these agents. Additional studies are needed to
better define the patient selection criteria, optimum
dosing and duration strategies, hospital costs and
long-term outcome. Another recent breakthrough in
this area has been the development of oral GP IIb/IIIa
blockers, which have the potential for long-term administration for the secondary prevention of coronary
artery disease. Large phase II and III trials are currently under way to evaluate the role of long-term inhibition with these oral agents. The high economic
costs of these pharmaceutical agents will unfortunately
be a major limiting factor in the wider use of these
therapies. Further cost-benefit analysis may help us to
understand the economics of glycoprotein IIb/IIIa
blockade therapy in different clinical settings.
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